These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

644 related articles for article (PubMed ID: 18079742)

  • 1. Drugs versus bugs: in pursuit of the persistent predator Mycobacterium tuberculosis.
    Sacchettini JC; Rubin EJ; Freundlich JS
    Nat Rev Microbiol; 2008 Jan; 6(1):41-52. PubMed ID: 18079742
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rising standards for tuberculosis drug development.
    Balganesh TS; Alzari PM; Cole ST
    Trends Pharmacol Sci; 2008 Nov; 29(11):576-81. PubMed ID: 18799223
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emerging drugs for active tuberculosis.
    Ginsberg AM
    Semin Respir Crit Care Med; 2008 Oct; 29(5):552-9. PubMed ID: 18810688
    [TBL] [Abstract][Full Text] [Related]  

  • 4. First-line anti-tuberculosis drug resistance patterns and trends at the national TB referral center in Iran--eight years of surveillance.
    Shamaei M; Marjani M; Chitsaz E; Kazempour M; Esmaeili M; Farnia P; Tabarsi P; Amiri MV; Mirsaeidi M; Mansouri D; Masjedi MR; Velayati AA
    Int J Infect Dis; 2009 Sep; 13(5):e236-40. PubMed ID: 19285897
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overcoming the global crisis: "yes, we can", but also for TB ... ?
    Ottenhoff TH
    Eur J Immunol; 2009 Aug; 39(8):2014-20. PubMed ID: 19672895
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tuberculosis drug resistance: summary report for 2003.
    Can Commun Dis Rep; 2004 May; 30(10):93-5. PubMed ID: 15174496
    [No Abstract]   [Full Text] [Related]  

  • 7. Extensively drug-resistant tuberculosis: current challenges and threats.
    Jain A; Mondal R
    FEMS Immunol Med Microbiol; 2008 Jul; 53(2):145-50. PubMed ID: 18479439
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-TB drug resistance levels and patterns among Mycobacterium tuberculosis isolated from newly diagnosed cases of pulmonary tuberculosis in Dar es Salaam, Tanzania.
    Matee M; Mfinanga S; Holm-Hansen C
    APMIS; 2009 Apr; 117(4):263-7. PubMed ID: 19338514
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tuberculosis: burning issues: multidrug resistance and HIV-coinfection.
    Janbaz KH; Qadir MI; Ahmad B; Sarwar A; Yaqoob N; Masood MI
    Crit Rev Microbiol; 2012 Nov; 38(4):267-75. PubMed ID: 22421086
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Persistence, not resistance, is the cause of loss of isoniazid effect.
    Wallis RS; Palaci M; Eisenach K
    J Infect Dis; 2007 Jun; 195(12):1870-1; author reply 1872-3. PubMed ID: 17492604
    [No Abstract]   [Full Text] [Related]  

  • 11. Peptide deformylase--a promising therapeutic target for tuberculosis and antibacterial drug discovery.
    Sharma A; Khuller GK; Sharma S
    Expert Opin Ther Targets; 2009 Jul; 13(7):753-65. PubMed ID: 19530983
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Isoniazid activity is terminated by bacterial persistence.
    Mitchison DA; Jindani A; Davies GR; Sirgel F
    J Infect Dis; 2007 Jun; 195(12):1871-2; author reply 1872-3. PubMed ID: 17492605
    [No Abstract]   [Full Text] [Related]  

  • 13. Managing TB in the 21st century: existing and novel drug therapies.
    Guy ES; Mallampalli A
    Ther Adv Respir Dis; 2008 Dec; 2(6):401-8. PubMed ID: 19124385
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The rate and pattern of drug resistance in Mycobacterium tuberculosis at various sites of the disease].
    Vishnevskiĭ BI; Steklova LN
    Probl Tuberk Bolezn Legk; 2008; (12):5-8. PubMed ID: 19227317
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current issues in global tuberculosis control.
    Frothingham R; Stout JE; Hamilton CD
    Int J Infect Dis; 2005 Nov; 9(6):297-311. PubMed ID: 16183319
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New perspectives on natural products in TB drug research.
    Pauli GF; Case RJ; Inui T; Wang Y; Cho S; Fischer NH; Franzblau SG
    Life Sci; 2005 Dec; 78(5):485-94. PubMed ID: 16243360
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extensively drug-resistant tuberculosis: new strains, new challenges.
    Banerjee R; Schecter GF; Flood J; Porco TC
    Expert Rev Anti Infect Ther; 2008 Oct; 6(5):713-24. PubMed ID: 18847407
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Facing the crisis: improving the diagnosis of tuberculosis in the HIV era.
    Perkins MD; Cunningham J
    J Infect Dis; 2007 Aug; 196 Suppl 1():S15-27. PubMed ID: 17624822
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical testing of new drugs for tuberculosis: current challenges.
    Lenaerts AJ; Degroote MA; Orme IM
    Trends Microbiol; 2008 Feb; 16(2):48-54. PubMed ID: 18182291
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Developing pyrrole-derived antimycobacterial agents: a rational lead optimization approach.
    Biava M; Porretta GC; Poce G; Battilocchio C; Alfonso S; de Logu A; Manetti F; Botta M
    ChemMedChem; 2011 Apr; 6(4):593-9. PubMed ID: 21341373
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.